KVUE vs PG: Kenvue vs Procter & Gamble Stock Comparison: AI Score, Valuation, Performance and Upside
Kenvue is a focused consumer health company with iconic self-care brands that was spun off from J&J in 2023, while P&G is the world's largest consumer staples company with 67+ years of consecutive dividend growth. P&G is the higher-quality, more diversified consumer staples compounder; Kenvue is the pure-play consumer health brand portfolio at a lower valuation with more focused management.
KVUE vs PG is a newly independent consumer health brand portfolio versus the world's most trusted consumer staples compounder — Kenvue wins if independence unlocks brand investment and margin improvement; P&G wins if pricing power, global scale, and dividend growth compound consistently.
PG holds the edge across 3 of 5 key metrics in this comparison. KVUE leads on both 1-year return (+14.82%) and forward P/E quality (15.37x vs 20.45x for PG), a relatively favorable combination of momentum and valuation. On fundamentals, KVUE is growing revenue faster (3.00%), while PG maintains the higher operating margin (22.08%) — a classic growth-versus-profitability split. Analyst consensus implies meaningfully more upside for PG (+6.60%) than for KVUE (+2.15%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- want focused consumer health brand exposure through Tylenol, Listerine, Neutrogena, and Band-Aid
- believe independence from J&J allows Kenvue to invest more efficiently in its specific brand portfolio
- value Kenvue's lower valuation vs P&G for similar consumer brand quality in the health category
- prefer a pure-play consumer health company over P&G's broader staples diversification
- want the world's most trusted consumer staples compounder with 67+ years of dividend growth
- value P&G's global scale, pricing power, and category leadership across essential household products
- prefer Dividend Aristocrat exposure with the longest track record in consumer goods
- are comfortable paying a premium multiple for P&G's durable brand quality and global distribution
| Metric | KVUE | PG |
|---|---|---|
| AI scorei | 23.9 | 41.6 |
| AI ranki | #3168 | #968 |
| Latest closei | $18.67 | $157.08 |
| 1M returni | +4.19% | +7.10% |
| 3M returni | -1.84% | +3.68% |
| 6M returni | +6.93% | +9.76% |
| 1Y returni | +14.82% | +6.55% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | KVUE | PG |
|---|---|---|
| 1Y ago | $13.23K (+32.3%) started 2025-10-16 | $10.5K (+5.0%) started 2025-10-16 |
| 5Y ago | $8.11K (-18.9%) started 2023-05-04 | $13.34K (+33.4%) started 2021-10-18 |
| 10Y ago | $8.11K (-18.9%) started 2023-05-04 | $29.59K (+195.9%) started 2016-10-17 |
Hypothetical — past performance does not guarantee future results.
| Metric | KVUE | PG |
|---|---|---|
| Market capi | $36.67B | $351.26B |
| Trailing P/Ei | 22.46 | 22.84 |
| Forward P/Ei | 15.37 | 20.45 |
| Price/Salesi | N/A | 4.58 |
| EV/Revenuei | 2.82 | 4.34 |
| Analyst targeti | $19.50 | $161.22 |
| Target upsidei | +2.15% | +6.60% |
| Metric | KVUE | PG |
|---|---|---|
| Revenue growthi | 3.00% | 1.50% |
| Earnings growthi | 8.50% | -15.50% |
| EPS growthi | +8.50% | -15.50% |
| FCF margini | +12.38% | +15.26% |
| Operating margini | 19.42% | 22.08% |
| Profit margini | 10.76% | 18.44% |
| ROIC proxyi | 15.58% | 30.29% |
| Return on equityi | 15.58% | 30.29% |
| Dividend yieldi | 4.48% | 2.88% |
| Payout ratioi | 96.51% | 64.33% |
| Dividend growth streaki | No increase yet | No increase yet |
| Betai | 0.43 | 0.38 |
| Debt/equityi | 81.62 | 64.49 |
| Current ratioi | 1.00 | 0.68 |
| Quick ratioi | 0.61 | 0.41 |
Over the past year, KVUE and PG have moved moderately in the same direction (correlation of 0.45), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | KVUE | PG |
|---|---|---|---|
| 1Y | Growthi | +32.32% | +5.00% |
| CAGRi | +32.38% | +5.01% | |
| Volatilityi | 25.59% | 19.72% | |
| Sharpe ratioi | 1.05 | 0.12 | |
| Sortino ratioi | 1.83 | 0.17 | |
| Max drawdowni | 13.26% | 16.15% | |
| Current drawdowni | 5.85% | 6.05% | |
| Avg drawdowni | 4.84% | 8.87% | |
| Ulcer Indexi | 6.18% | 10.14% | |
| Max daily dropi | 3.92% | 3.56% | |
| Max wkly dropi | 7.00% | 8.12% | |
| 5Y | Growthi | -25.07% | +21.07% |
| CAGRi | -8.02% | +3.90% | |
| Volatilityi | 28.00% | 18.20% | |
| Sharpe ratioi | -0.32 | 0.06 | |
| Sortino ratioi | -0.46 | 0.08 | |
| Max drawdowni | 44.61% | 23.77% | |
| Current drawdowni | 26.70% | 11.51% | |
| Avg drawdowni | 22.01% | 8.50% | |
| Ulcer Indexi | 23.86% | 10.56% | |
| Max daily dropi | 13.22% | 6.23% | |
| Max wkly dropi | 16.21% | 8.92% | |
| 10Y | Growthi | -25.07% | +126.58% |
| CAGRi | -8.02% | +8.53% | |
| Volatilityi | 28.00% | 19.21% | |
| Sharpe ratioi | -0.32 | 0.29 | |
| Sortino ratioi | -0.46 | 0.41 | |
| Max drawdowni | 44.61% | 23.77% | |
| Current drawdowni | 26.70% | 11.51% | |
| Avg drawdowni | 22.01% | 6.64% | |
| Ulcer Indexi | 23.86% | 8.95% | |
| Max daily dropi | 13.22% | 8.74% | |
| Max wkly dropi | 16.21% | 16.27% |
| Category | KVUE | PG |
|---|---|---|
| Company | Kenvue Inc. | The Procter & Gamble Company |
| Sector | Consumer Defensive | Consumer Defensive |
| Industry | Household & Personal Products | Household & Personal Products |
| Core business | Consumer health company spun off from Johnson & Johnson in 2023 with iconic self-care brands including Tylenol, Neutrogena, Listerine, Band-Aid, Aveeno, and Nicorette. Kenvue operates across three segments: skin health & beauty, essential health, and self care. | World's largest consumer staples company with Tide, Pampers, Gillette, Head & Shoulders, Oral-B, Always, Bounty, Febreze, and Charmin among its brand portfolio. P&G serves consumers in 180+ countries. |
| Investor focus | Organic revenue growth across skin health and essential health segments, Neutrogena brand recovery, margin improvement, and dividend sustainability post-separation. | Organic revenue growth from pricing and volume, market share across core categories, emerging market penetration, and dividend growth (67+ consecutive years of dividend increases). |
- Portfolio of #1 or #2 market-share brands in self-care categories creates durable consumer demand
- Tylenol, Listerine, and Band-Aid are generational brands with extremely high consumer trust and repurchase rates
- Independent company structure allows Kenvue to focus capital and management attention entirely on consumer health
- P&G's portfolio of #1 brands across essential categories (laundry, diapers, shaving, feminine care) represents the most trusted consumer staples franchise globally
- Pricing power through premium brand investment allows P&G to pass through commodity cost inflation while protecting margins
- 67+ years of consecutive dividend increases make P&G one of the most reliable dividend growth stocks in the world
- Some Kenvue brands face generic and private-label competition in drugstores and mass retail channels
- Neutrogena has faced brand challenges and increased competition in the skin care category
- Kenvue carries post-separation debt that limits capital allocation flexibility vs a debt-free consumer staples company
- Private-label share gains in inflationary environments put volume pressure on branded consumer staples
- P&G trades at a premium multiple that embeds a high-quality assumption — any organic growth slowdown can cause multiple compression
- Emerging market FX headwinds from local currency depreciation affect USD-reported results despite strong local volume growth
Compare more than two at a time
This page is a fixed writeup on KVUE and PG. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside KVUE and PG, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.